← Earnings Calls
CL FY2025 Q4 In line

Colgate-Palmolive Company earnings call

Jan 30, 2026 · 08:30 ET John CochetNoel WallaceStan Satula earningscall_biz
Buzzberg read

Wider 2026 guidance range reflects category uncertainty

Colgate-Palmolive reported stronger-than-expected Q4 2025 results, with organic sales growth in all four categories and sequential improvement. Management guides for a wide 1-4% organic sales growth range for 2026, citing stabilized but low category growth, a sluggish U.S. market, and volatile geopolitical environment. Q4 organic sales growth was just above 3% excluding private label and divestitures, with volume growth returning.

Buzzberg read Wider 2026 guidance range reflects category uncertainty Colgate-Palmolive reported stronger-than-expected Q4 2025 results, with organic sales growth in all four categories and sequential improvement. Management guides for a wide 1-4% organic sales growth range for 2026, citing stabilized but low category growth, a sluggish U.S. market, and volatile geopolitical environment. Q4 organic sales growth was just above 3% excluding private label and divestitures, with volume growth returning. Read full analysisCollapse analysis

Colgate-Palmolive reported stronger-than-expected Q4 2025 results, with organic sales growth in all four categories and sequential improvement. Management guides for a wide 1-4% organic sales growth range for 2026, citing stabilized but low category growth, a sluggish U.S. market, and volatile geopolitical environment. Q4 organic sales growth was just above 3% excluding private label and divestitures, with volume growth returning.

  • Management provided 2026 organic sales growth guidance of 1-4%, a wider range than normal due to uncertainty.
  • Emerging markets, especially Latin America and Africa-Eurasia, are performing ahead of developed markets.
  • The U.S. market remains sluggish, though management sees improvement and a stronger innovation pipeline for 2026.
Revenue$5.23BReported
EPS$0.95Reported
Gross margin60.15%Reported
Operating margin20.59%Reported
6 grounded callouts

What matters now

The highest-signal changes from the call.

01
Guidance

Wider 2026 guidance range reflects category uncertainty

02
Strategy

2030 strategy focuses on five key growth areas

03
Demand

Q4 organic growth improved across all categories

Show 3 more callouts
04
Macro

FX expected to be low single-digit benefit to 2026 revenue

05
Demand

Hills outperformed despite category softness

06
Margins

Strategic Growth and Productivity Program to drive structural changes

Reported period

Actuals

MetricReportedChange
Revenue$5.23BReported
EPS$0.95Reported
Gross margin60.15%Reported
Operating margin20.59%Reported
Free cash flow$1.276BReported
Capex$0.177BReported
Forward-looking

Forward guidance

MetricPeriodRangeMidpointStatus
RevenueFY20261%–4%2.5%Guided
AI, capex & demand read

Management read

Tone

Measured

Management expressed confidence in the strategy and resilience, but acknowledged significant uncertainty and volatility in the environment, and gave a wider-than-normal guidance range.

AI

Management AI read

Management discussed AI as a key part of their 2030 strategy, focusing on scaling capabilities in digital, data, analytics, and AI to drive faster growth, efficiency, and productivity, including in revenue growth management and supply chain optimization.

Capex

Investment and capacity

Management did not provide specific capex guidance, but highlighted investments in new facilities, R&D, and capabilities as a priority for capital allocation, including past investments in Red Collar and Prime 100.

all 4 named companies below

Companiesreturns since call

Supply chain

Supply chain

Despite a tough North American market with categories declining, Colgate saw a sequential improvement in December versus October and November in terms of category volume declines, and is planning for a 'slow return' rather than a sharp rebound. — The stability in the U.S. consumer packaged goods market may be a leading indicator for competitors; the lack of a strong rebound suggests continued promotional intensity in the first half of 2026.

Evidence
“Nine of our categories were down in volume in the U.S. in October and 10 in November. That's category numbers. It was only six in December, so as I mentioned, improved a little bit.”
Noel Wallace
Supply chain

Colgate is seeing a 'K-shaped' market, with growth in super premium and value segments, while the middle is being squeezed, particularly in emerging markets like Latin America. — This dynamic could pressure competitors with a heavier presence in mid-tier products, forcing them to lean into premium innovation or value brands to maintain market share.

Evidence
“We are seeing some of the middle get squeezed in Latin America as well, where the super premium continues to grow quite nicely. The value segment is growing where the middle is getting squeezed.”
Noel Wallace
External signals

Supply-chain alpha · 3returns since call

A1

Hills Science Diet is gaining share across all channels despite the sluggish pet category, driven by prescription diet and therapeutic growth.

Evidence
“But overall, We're very pleased with the continued progress, but the category continues to remain quite sluggish. And we've seen some of the issues up in Canada with the bi-Canadian on the business, but overall, On a broad basis, we're ver…”
A2

Despite a tough North American market with categories declining, Colgate saw a sequential improvement in December versus October and November in terms of category volume declines, and is planning for a 'slow return' rather than a sharp rebound.

A3

Colgate is seeing a 'K-shaped' market, with growth in super premium and value segments, while the middle is being squeezed, particularly in emerging markets like Latin America.

Methodology & coverage

Management-only analysis. All 4 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.